跳转至内容
Merck
CN
  • The "Performance of Rotavirus and Oral Polio Vaccines in Developing Countries" (PROVIDE) study: description of methods of an interventional study designed to explore complex biologic problems.

The "Performance of Rotavirus and Oral Polio Vaccines in Developing Countries" (PROVIDE) study: description of methods of an interventional study designed to explore complex biologic problems.

The American journal of tropical medicine and hygiene (2015-02-26)
Beth D Kirkpatrick, E Ross Colgate, Josyf C Mychaleckyj, Rashidul Haque, Dorothy M Dickson, Marya P Carmolli, Uma Nayak, Mami Taniuchi, Caitlin Naylor, Firdausi Qadri, Jennie Z Ma, Masud Alam, Mary Claire Walsh, Sean A Diehl, William A Petri
摘要

Oral vaccines appear less effective in children in the developing world. Proposed biologic reasons include concurrent enteric infections, malnutrition, breast milk interference, and environmental enteropathy (EE). Rigorous study design and careful data management are essential to begin to understand this complex problem while assuring research subject safety. Herein, we describe the methodology and lessons learned in the PROVIDE study (Dhaka, Bangladesh). A randomized clinical trial platform evaluated the efficacy of delayed-dose oral rotavirus vaccine as well as the benefit of an injectable polio vaccine replacing one dose of oral polio vaccine. This rigorous infrastructure supported the additional examination of hypotheses of vaccine underperformance. Primary and secondary efficacy and immunogenicity measures for rotavirus and polio vaccines were measured, as well as the impact of EE and additional exploratory variables. Methods for the enrollment and 2-year follow-up of a 700 child birth cohort are described, including core laboratory, safety, regulatory, and data management practices. Intense efforts to standardize clinical, laboratory, and data management procedures in a developing world setting provide clinical trials rigor to all outcomes. Although this study infrastructure requires extensive time and effort, it allows optimized safety and confidence in the validity of data gathered in complex, developing country settings.

材料
产品编号
品牌
产品描述

Sigma-Aldrich
D -甘露醇, ≥98% (GC)
Supelco
甘露醇, Pharmaceutical Secondary Standard; Certified Reference Material
Sigma-Aldrich
D -甘露醇, ACS reagent
Sigma-Aldrich
D -甘露醇, ≥98% (GC), suitable for plant cell culture
USP
甘露醇, United States Pharmacopeia (USP) Reference Standard
Sigma-Aldrich
Lactulose, ≥98.0% (HPLC)
Sigma-Aldrich
D -甘露醇, BioUltra, ≥99.0% (sum of enantiomers, HPLC)
Sigma-Aldrich
D -甘露醇, meets EP, FCC, USP testing specifications
Sigma-Aldrich
D -甘露醇, BioXtra, ≥98% (HPLC)
甘露醇, European Pharmacopoeia (EP) Reference Standard
Sigma-Aldrich
Lactulose, ≥95% (HPLC)
Supelco
乳果糖, Pharmaceutical Secondary Standard; Certified Reference Material
Millipore
D -甘露醇, ACS reagent, suitable for microbiology, ≥99.0%
Sigma-Aldrich
D -甘露醇, tested according to Ph. Eur.
USP
Lactulose, United States Pharmacopeia (USP) Reference Standard
Supelco
D -甘露醇, ≥99.9999% (metals basis), for boron determination
Sigma-Aldrich
β-D-阿洛糖, rare aldohexose sugar
Lactulose, European Pharmacopoeia (EP) Reference Standard